Dr Richard J. Milne BSc (Hons), MSc, PhD
Managing Director, Health Outcomes Associates Ltd; Associate Professor, School of Population Health, The University of Auckland, Auckland, NZ
Milne trained in physics/maths, physiology/ pharmacology, neuroscience and
health economics in NZ and the USA. He has been researching the epidemiology
and economics of healthcare interventions since 1997. Richard has published
over 50 peer-reviewed articles in physics, physiology, pharmacology, medical
statistics, ethics and health economics and is an Advisory Board member on the
leading peer-reviewed Journal PharmacoEconomics, of which he was the
founding Editor. He was also the
founding President of the NZ chapter of the International Society for
Pharmacoeconomics & Outcomes Research.
From Wo to Go, and
Beyond - The Role of Economic Evaluation in Product Development, Funding &
Economic evaluation is
the process of linking costs to outcomes in order to evaluate the cost-effectiveness of interventions compared to other interventions within the same
budget. Over the last 30 years, economic evaluation has become a sophisticated
industry, especially in Europe and the USA. It is also widely used in Asian
countries and in Latin America, and is performed by academics, consultancy
groups, health care funding agencies such as PHARMAC, and increasingly by the
health insurance industry and healthcare providers including District Health
Boards in NZ.
This presentation will outline the role of economic evaluation in informing the development, funding and outcome assessment of new products including pharmaceuticals, caccines and medical devices.